Barbara Burtness, MD
Medical Oncology · New Haven, CTNPI 1194715649
Payments from drug & device makers
Across 513 payments — averaging $6046.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.7M
- GSK$138K
- E.r. Squibb & Sons, L.L.C.$94K
- Exelixis Inc.$68K
- Astrazeneca UK Limited$25K
- EMD Serono, Inc.$13K
- plus $98K from 20 others
Across 9 payments — averaging $5249.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$41K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- EMD Serono, Inc.$2K
- GSK$263
What the payments were for
- Consulting fees$193,54265%
- Speaking & faculty fees$35,79012%
- Travel & lodging$64,71922%
- Food & beverage$2,5731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 282 | $2,666,144 |
| GSK | 98 | $138,147 |
| E.r. Squibb & Sons, L.L.C. | 5 | $94,027 |
| Exelixis Inc. | 40 | $67,609 |
| Astrazeneca UK Limited | 12 | $24,845 |
| EMD Serono, Inc. | 4 | $12,922 |
| AbbVie | 9 | $11,688 |
| Genmab U.S., Inc. | 12 | $11,582 |
| Merck Kgaa | 7 | $8,288 |
| Genentech, Inc. | 3 | $6,700 |
| Janssen Research & Development, LLC | 3 | $6,615 |
| Merck Healthcare Kgaa | 6 | $6,583 |
| Eisai Inc. | 3 | $6,550 |
| EMD Serono Research & Development Institute, Inc. | 1 | $6,522 |
| Coherus Oncology, Inc. | 3 | $6,375 |
| Pfizer | 7 | $5,949 |
| Sentrimed, Inc. | 1 | $4,000 |
| Janssen Global Services, LLC | 5 | $3,411 |
| Ipsen Bioscience Inc. | 2 | $3,020 |
| Astellas Pharma Global Development | 1 | $2,700 |
| Dr.reddy's Laboratories,inc. | 1 | $2,500 |
| Seagen Inc. | 4 | $1,982 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,842 |
| Ipsen Pharma SAS | 1 | $910 |
| Urogen Pharma, Inc. | 1 | $690 |
| Amgen | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,101,603 in reported general payments places this provider in the 85th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 15 | $524 |
| Levothyroxine Sodium | 18 | $56 |
| Sodium FluorideFluoride (Sodium) | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Haven
- Lajos PusztaiNew Haven$23.5M
- Sarah GoldbergNew Haven$17.7M
- Harriet KlugerNew Haven$17.7M
- Daniel PetrylakNew Haven$10M
- Ian KropNew Haven$7.5M
- Anne ChiangNew Haven$5.8M
- Noffar BarNew Haven$5.4M
- Scott GettingerNew Haven$5.1M
- Jill LacyNew Haven$3.5M
- Aarti BhatiaNew Haven$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.